Penserra Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Penserra Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,080	Closed	-$12K	–	1625
2021 Q3	$12K	Buy	1,080 +15	+1%	+$219	﹤0.01%	1340
2021 Q2	$17K	Hold	1,065	–	–	﹤0.01%	1193
2021 Q1	$19K	Sell	1,065 -10	-0.9%	-$173	﹤0.01%	978
2020 Q4	$14K	Buy	1,075 +679	+171%	+$8.21K	﹤0.01%	895
2020 Q3	$4K	Buy	+396	New	+$4.82K	﹤0.01%	877

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Penserra Capital Management's AERI Position: Q4 2021 in Review

Penserra Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2021, closing a stake of 1,080 shares — an estimated $12K sold.

Penserra Capital Management first reported a position in AERI in Q3 2020 and held it in 5 quarters. The position peaked at $19K in Q1 2021. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

Penserra Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 1,080 Aerie Pharmaceuticals shares in Q4 2021, an estimated $12K.
Penserra Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2020 and held it in 5 quarters.
Penserra Capital Management's Aerie Pharmaceuticals position peaked at $19K in Q1 2021.
129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.